Safety and Efficacy of Carbon Ion and Proton Therapies for Pancreatic Cancer: A Systematic Review and Meta-analysis
-
摘要:目的
评价碳离子和质子治疗胰腺癌（PaC）的安全性和有效性。
方法检索数据库纳入碳离子和质子治疗PaC的临床研究，检索时间为自建库至2019年6月。两位研究者独立筛选文献、提取资料。采用STATA 12.0和MetaAnalyst Beta 3.13软件进行Meta分析。
结果共纳入8篇文献，包含459例PaC患者。效应模型Meta分析显示，碳离子和质子治疗PaC的2、3、5级胃肠道溃疡发生率分别为7%、2%、0；2、3、4级厌食症发生率分别为6%、3%、0；1、2年总生存率（OS）分别为77%、45%；2年局部控制率为81%；1年无局部进展率为88%；1年局部复发率为15%。碳离子和质子治疗PaC的2、3、2~3级胃肠道溃疡发生率分别为6.8%、1.5%、9.2%和3.5%、8.3%、6.1%（均P < 0.05）；1、2年OS分别为77.1%、44.4%和77.6%、49.7%（P均 > 0.05）。
结论碳离子和质子治疗PaC安全有效，两者的安全性和有效性相似。
Abstract:ObjectiveTo evaluate the safety and efficacy of carbon ion and proton therapies for pancreatic cancer (PaC).
MethodsThe databases were electronically searched to collect the studies about the carbon ion and proton therapies for PaC from inception to June 2019. Two reviewers independently screened literature and extracted data. A Meta-analysis was performed by STATA 12.0 and MetaAnalyst Beta 3.13 software.
ResultsA total of 8 studies involving 459 PaC patients were included. The incidence of grade 2, 3 and 5 gastrointestinal (GI) ulcer toxicities in PaC patients treated with carbon ion and proton therapies were 7%, 2% and 0; the incidence of grade 2, 3 and 4 anorexia toxicities were 6%, 3.2% and 0; the 1- and 2-year OS rates were 77% and 45%; the 2-year local control (LC), 1-year freedom from local progression (FFLP) and 1-year local recurrence(LR) rates were 81%, 88% and 15%. The incidence of grade 2, 3, 2-3 GI ulcer toxicities in carbon ion and proton therapies for PaC were 6.8%, 1.5%, 9.2% and 3.5%, 8.3%, 6.1% (P < 0.05); and the 1- and 2-year OS were 77.1%, 44.4% and 77.6%, 49.7% (P > 0.05).
ConclusionCarbon ion and proton therapies for PaC are safe and effective; and the security and effectiveness of the two methods are similar.
-
Key words:
- Carbon ion /
- Proton /
- Pancreatic cancer /
- Systematic review /
- Meta-analysis
-
0 引言
宫颈小细胞神经内分泌癌（small cell neuroendocrine carcinoma, SCNEC）是一种较为罕见的原发于宫颈的神经内分泌性肿瘤，约占宫颈恶性肿瘤的1%~2%[1-2]。在各种类型的宫颈癌中，SCNEC是一种侵袭性强的病理类型[3-8]。但因为该类病例较少，目前尚无规范化的治疗。本研究对101例宫颈小细胞神经内分泌癌患者的临床病理资料及生存状况进行分析，旨在探讨SCNEC合理的治疗方案及预后相关因素，为此类患者治疗及预后判断提供临床依据。
1 资料与方法
1.1 临床资料
收集2007年1月—2018年6月在江西省妇幼保健院确诊并完成治疗的101例宫颈小细胞神经内分泌癌患者作为研究对象。患者确诊年龄25~73岁，中位年龄44岁，其中41~50岁者有40例。宫颈局部肿瘤直径 > 4 cm患者34例，≤4 cm患者67例。患者临床资料及年龄分布见表 1。所有患者均知情同意。
表 1 101例SCNEC患者临床病理特征Table 1 Clinical and pathological features of 101 SCNEC patients
1.2 方法
1.2.1 研究对象纳入标准
（1）所有患者接受治疗前均经江西省妇幼保健院病理确诊为宫颈小细胞神经内分泌癌；（2）临床分期盆腔检查均经三位以上有经验的妇科肿瘤专业医师检查确定；（3）治疗前均未接受任何干预性治疗，且初始治疗及后续治疗均在同一机构完成；（4）纳入研究的患者治疗模式均为手术+术后补充放化疗（下文简称手术治疗组）或根治性放化疗，且按计划完成全部治疗；（5）全部患者术后病理检查均在同一医院完成；（6）建立了完整的病历档案，并持续随访，具备完整的住院及门诊复查病历资料。
1.2.2 手术方式
72例手术治疗患者手术方式为广泛子宫切除+盆腔淋巴结切除术±腹主动脉旁淋巴结切除术，其中47例行腹主动脉旁淋巴结切除术。69例行双附件切除，其余3例保留一侧卵巢且进行了保留卵巢的组织活检。
1.2.3 放疗
放疗包括体外照射+腔内后装治疗，体外照射采用全盆腔体外照射+中央遮盖体外照射。体外照射剂量：全盆照射肿瘤剂量30~40 Gy，中央遮盖照射剂量15~25 Gy，放疗频率及强度：每周5次，每次分割剂量2 Gy。腔内后装采用高剂量率后装治疗设备，放射源为铱192。放疗剂量参照点A点累积剂量要求60~70 Gy；B点累积剂量要求54~56 Gy。放疗期间均给予铂类为基础的同步化疗。
1.2.4 随访
通过电话或门诊复查方式进行随访，截止时间为2018年9月。
1.3 统计学方法
采用GraphPad7.0统计软件对不同组间患者生存率进行显著性比较。生存分析采用Kaplan-Meier法，生存率的比较采用Log rank检验。P < 0.05为差异有统计学意义。
2 结果
72例手术组患者中，2例失访，19例死亡，51例生存。19例死亡患者生存时间1~63月，中位生存时间19月，平均生存时间18.5月。51例生存的患者中，生存时间1~139月，中位生存时间39月，平均生存时间47.3月。随访5年以上共33例，生存20例，五年生存率60.6%。
29例根治性放化疗患者中，随访5年以上20例，其中2例失访，死亡15例，生存3例，五年生存率15%。生存时间1~75月，中位生存时间21月。3例生存患者年龄分别为40岁、41岁、46岁，临床分期均为ⅡB期，病理均为单纯的宫颈小细胞神经内分泌癌，化疗方案均为多西他赛+卡铂，放疗给予根治性同步放化疗。ⅠB1期~ⅡA期手术治疗组患者生存率优于ⅡB期~Ⅳ期期根治性放化疗组患者（P=0.0025），见图 1。
72例接受手术治疗的患者均行宫颈癌根治术+盆腔淋巴结切除术，47例行腹主动脉旁淋巴结切除术，其中1例（1/47, 2.12%）腹主动脉旁淋巴结阳性。27例（27/72, 37.5%）盆腔淋巴结阳性。淋巴结阳性与阴性患者生存曲线比较差异有统计学意义，淋巴结阴性患者生存优于淋巴结阳性患者（P=0.0004），见图 2。
![]()
图 2 盆腔淋巴结阳性和阴性手术患者生存曲线Figure 2 Survival curves of surgical SCNEC patients with pelvic lymph node positive and negative72例手术治疗的患者中，按病理类型分，单纯SCNEC例41例，混合其他病理类型者31例，其中混合有腺癌19例，鳞癌9例，腺鳞癌3例。混合型与单纯型SCNEC生存曲线比较差异无统计学意义（P=0.0546），见图 3。
3 讨论
WHO分类将宫颈神经内分泌肿瘤分为低级别神经内分泌肿瘤（包括类癌及非典型类癌）和高级别神经内分泌肿瘤（包括小细胞神经内分泌癌和大细胞神经内分泌癌）。目前无公认的、规范有效的治疗方案，对于宫颈神经内分泌肿瘤多参照常见宫颈癌的分期治疗原则，主张手术、化疗和放疗的综合性治疗，但其治疗是否应有别于宫颈鳞癌需要更大样本、多中心的研究。美国国立综合癌症网络（National Comprehensive Cancer Network, NCCN）指南也将SCNEC列入特殊类型宫颈癌。
关于SCNEC患者生存率及预后方面的研究，Ishikawa等的一项多中心研究显示淋巴血管间隙受侵是患者的总生存率及无进展生存率的重要预后因素，盆腔淋巴结转移是DFS的重要预后影响因素[9]。Cohen等研究发现Ⅰ~ⅡA、ⅡB~ⅣA、ⅣB期5年生存率分别为36.8%、9.8%和0[10]，本研究结果显示临床分期与预后密切相关，各期别5年生存率均较以往文献报道略高。FIGO分期是较为公认的影响患者预后的最重要的独立危险因素[11-12]。由于SCNEC侵袭性强，易发生远处转移，有学者认为早期SCNEC患者手术联合化疗的预后优于单纯手术者[13-14]。本研究中ⅠB~ⅡA期患者均采用手术+放化疗综合治疗，5年总生存率60%以上，提示手术联合术后放化疗对此类患者疗效较好。
宫颈小细胞神经内分泌癌早期容易发生转移，但从72例早期患者手术情况发现，仅1例（1.39%）发生卵巢转移。提示对于存在生育要求的年轻SCNEC患者，是否一定要行卵巢切除有待进一步研究证实。研究证实，SCNEC好发转移器官为肺、脑、肝，预后差[15-16]。
此外，几乎所有文献均支持此类肿瘤早期即容易发生远处转移，本研究资料中，死亡病例主要病因为肺转移、全身转移，临床观察也支持上述观点。关于淋巴结转移，有研究认为，即使是早期的SCNEC患者，淋巴结转移也非常普遍，淋巴结转移率为41.6%~57%[17]。本研究中，72例早期SCNEC患者手术后病理提示淋巴结转移22例，转移率37.5%，与文献报道接近，但是对于腹主动脉旁淋巴结，72例患者中47例患者行腹主动脉旁淋巴结活检或切除，仅1例发生腹主动脉旁淋巴结转移，转移率仅为2.13%，远低于盆腔淋巴结转移率。这一研究结果提示我们，即便是早期SCNEC患者，化疗对于控制转移也有重要的临床意义。
与以往报道相比，本研究中手术患者术后均补充了放化疗，且均达到6个疗程，其中49例采用紫杉醇+铂类化疗方案，23例采用顺铂+环磷酰胺+表阿霉素化疗方案，提示手术后放化疗的必要性。
总之，宫颈小细胞神经内分泌癌发病率低、恶性程度高、易发生远处转移和复发，患者预后差、死亡率高、有独特的病理特征，诊断主要依据病理诊断和免疫组织化学结果可提高其诊断的准确率。由于研究样本少，尚需大量的临床资料及多中心研究探索最佳早期诊断及治疗的方法。
作者贡献廖亦然：文献检索与筛选、数据提取与分析、论文撰写张秋宁：文献删改、修改论文邵丽华、刘锐锋、罗宏涛：文献筛选、数据提取王丽娜、冯双午：文献质量评价杨克虎：论文指导王小虎：全文统筹、研究构思与设计 -
表 2 纳入病例系列研究的偏倚风险评价结果
Table 2 Bias risk evaluation results of included case series studies
下载: 导出CSV
表 3 碳离子和质子治疗胰腺癌安全性和疗效评价指标的Meta分析结果
Table 3 Meta analysis results of safety and efficacy evaluation indicators of carbon ion and proton therapies for pancreatic cancer
下载: 导出CSV
表 4 碳离子和质子治疗胰腺癌在不良反应和OS方面的差异
Table 4 Differences in adverse reactions and OS between carbon ion and proton therapies for pancreatic cancer
下载: 导出CSV
-
[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1): 7-34. doi: 10.3322/caac.21551
[2] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. doi: 10.3322/caac.21338
[3] Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States[J]. Cancer Res, 2014, 74(11): 2913-2921. doi: 10.1158/0008-5472.CAN-14-0155
[4] Chong HK, Wang T, Lu HM, et al. The validation and clinical implementation of BRCAplus: a comprehensive high-risk breast cancer diagnostic assay[J]. PLoS One, 2014, 9(5): e97408. doi: 10.1371/journal.pone.0097408
[5] 毛铁波, 崔玖洁, 王理伟.胰腺癌综合治疗的进展与突破[J].循证医学, 2019, 19(5): 257-260. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=xzyx201905001 Mao TB, Cui JJ, Wang LW. Progress and Breakthrough in The Comprehensive Treatment of Pancreatic Cancer[J]. Xun Zheng Yi Xue, 2019, 19(5): 257-260.] http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=xzyx201905001
[6] Janssen QP, Buettner S, Suker M, et al. Neoadjuvant FOLFIRINO X in patients with borderline resectable pancreatic cancer:A systematic review and patient-level meta-analysis[J]. J Natl Cancer Inst, 2019, 111(8): 782-794. doi: 10.1093/jnci/djz073
[7] Ciabatti S, Cammelli S, Frakulli R, et al. Radiotherapy of pancreatic cancer in older patients: A systematic review[J]. J Geriatr Oncol, 2019, 10(4): 534-539. doi: 10.1016/j.jgo.2018.09.007
[8] Sakurai H, Ishikawa H, Okumura T. Proton beam therapy in Japan: current and future status[J]. Jpn J Clin Oncol, 2016, 46(10): 885-892. doi: 10.1093/jjco/hyw102
[9] Hong TS, Wo JY, Borger DR, et al. Phase Ⅱ Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype[J]. J Natl Cancer Inst, 2017, 109(9). https://pubmed.ncbi.nlm.nih.gov/28954285/
[10] 王小琴, 陈耀龙, 渠清源, 等.病例系列研究方法学质量评价工具解读[J].中国循证儿科杂志, 2015, 10(5): 381-385. doi: 10.3969/j.issn.1673-5501.2015.05.012 Wang XQ, Chen YL, Qu QY, et al. Interpretation of methodological quality assessment tools for case series studies[J]. Zhongguo Xun Zheng Er Ke Za Zhi, 2015, 10(5): 381-385.] doi: 10.3969/j.issn.1673-5501.2015.05.012
[11] Terashima K, Demizu Y, Hashimoto N, et al. A phaseⅠ/Ⅱ study of gemcitabine-concurrent proton radiotherapy for locally advanced pancreatic cancer without distant metastasis[J]. Radiother Oncol, 2012, 103(1): 25-31. https://pubmed.ncbi.nlm.nih.gov/22300608/
[12] Shinoto M, Yamada S, Terashima K, et al. Carbon Ion Radiation Therapy With Concurrent Gemcitabine for Patients With Locally Advanced Pancreatic Cancer[J]. Int J Radiat Oncol Biol Phys, 2016, 95(1): 498-504. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=f015ae31b5fe103046d093741a32333c
[13] Maemura K, Mataki Y, Kurahara H, et al. Comparison of proton beam radiotherapy and hyper-fractionated accelerated chemoradiotherapy for locally advanced pancreatic cancer[J]. Pancreatology, 2017, 17(5): 833-838. doi: 10.1016/j.pan.2017.07.191
[14] Hiroshima Y, Fukumitsu N, Saito T, et al. Concurrent chemoradiotherapy using proton beams for unresectable locally advanced pancreatic cancer[J]. Radiother Oncol, 2019, 136: 37-43. doi: 10.1016/j.radonc.2019.03.012
[15] Shinoto M, Shioyama Y, Matsunobu A, et al. Dosimetric analysis of upper gastrointestinal ulcer after carbon-ion radiotherapy for pancreatic cancer[J]. Radiother Oncol, 2016, 120(1): 140-144. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=b773f9899123be5d5860c7dbe2914625
[16] Kawashiro S, Yamada S, Okamoto M, et al. Multi-institutional Study of Carbon-ion Radiotherapy for Locally Advanced Pancreatic Cancer: Japan Carbon-ion Radiation Oncology Study Group (J-CROS) Study 1403 Pancreas[J]. Int J Radiat Oncol Biol Phys, 2018, 101(5): 1212-1221. doi: 10.1016/j.ijrobp.2018.04.057
[17] Shinoto M, Terashima K, Suefuji H, et al. A single institutional experience of combined carbon-ion radiotherapy and chemotherapy for unresectable locally advanced pancreatic cancer[J]. Radiother Oncol, 2018, 129(2): 333-339. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=a2eaf8e052763b1f808a5ac867dcbb95
[18] Takatori K, Terashima K, Yoshida R, et al. Upper gastrointestinal complications associated with gemcitabine-concurrent proton radiotherapy for inoperable pancreatic cancer[J]. J Gastroenterol, 2014, 49(6): 1074-1080. doi: 10.1007/s00535-013-0857-3
[19] Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or Gemcitabine as adjuvant therapy for pancreatic cancer[J]. N Engl J Med, 2018, 379(25): 2395-2406. doi: 10.1056/NEJMoa1809775
[20] Katz MH, Shi Q, Ahmad SA, et al. Preoperative modified FOLFIRINOX treatment followed by Capecitabine-based chemoradiation for borderline resectable pancreatic cancer:Alliance for clinical trials in oncology trial A021101[J]. JAMA Surg, 2016, 151(8): e161137. doi: 10.1001/jamasurg.2016.1137
[21] Janssen QP, Buettner S, Suker M, et al. Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: A systematic review and patient-level meta-analysis[J]. J Natl Cancer Inst, 2019, 111(8): 782-794. doi: 10.1093/jnci/djz073
[22] Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus Gemcitabine for metastatic pancreatic cancer[J]. N Engl J Med, 2011, 364(19): 1817-1825. doi: 10.1056/NEJMoa1011923
[23] Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nab-Paclitaxel is an active regimen in patients with advanced pancreatic cancer: A phase Ⅰ/Ⅱ trial[J]. J Clin Oncol, 2011, 29(34): 4548-4554. doi: 10.1200/JCO.2011.36.5742
[24] Chiorean EG, Cheung WY, Giordano G, et al. Real-world comparative effectiveness of nab-Paclitaxel plus Gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: A systematic review[J]. Ther Adv Med Oncol, 2019, 11: 1758835919850367. https://www.researchgate.net/publication/333217022_Real-world_comparative_effectiveness_of_nab-paclitaxel_plus_gemcitabine_versus_FOLFIRINOX_in_advanced_pancreatic_cancer_a_systematic_review
[25] Golan T, Hammel P, Reni M, et al. Maintenance Olaparib for germline BRCA-mutated metastatic pancreatic cancer[J]. N Engl J Med, 2019, 381(4): 317-327. doi: 10.1056/NEJMoa1903387
[26] Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection[J]. Arch Surg, 1985, 120(8): 899-903. doi: 10.1001/archsurg.1985.01390320023003
[27] Fogel EL, Shahda S, Sandrasegaran K, et al. A multidisciplinary Approach to Pancereas Cancer in 2016: A Review[J]. Am J Gastroenterol, 2017, 112(4): 537-554. doi: 10.1038/ajg.2016.610
[28] Smeenk HG, van Eijck CH, Hop WC, et al. Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891[J]. Ann Surg, 2007, 246(5): 734-740. doi: 10.1097/SLA.0b013e318156eef3
[29] Iacobuzio-Donahue CA, Fu B, Yachida S, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer[J]. J Clin Oncol, 2009, 27(11): 1806-1813. doi: 10.1200/JCO.2008.17.7188
[30] Hammel P, Huguet F, van Laethem JL, et al. Effect of Chemoradiotherapy vs. Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial[J]. JAMA, 2016, 315(17): 1844-1853. doi: 10.1001/jama.2016.4324
[31] Ng SP, Herman JM. Stereotactic Radiotherapy and Particle Therapy for Pancreatic Cancer[J]. Cancers (Basel), 2018, 10(3):75. doi: 10.3390/cancers10030075
[32] Uhl M, Mattke M, Welzel T, et al. High control rate in patients with chondrosarcoma of the skull base after carbon ion therapy: first report of long-term results[J]. Cancer, 2014, 120(10): 1579-1585. doi: 10.1002/cncr.28606
[33] Sahgal A, Chan MW, Atenafu EG, et al. Image-guided, intensity-modulated radiation therapy (IG-IMRT) for skull base chordoma and chondrosarcoma: preliminary outcomes[J]. Neuro Oncol, 2015, 17(6): 889-894. doi: 10.1093/neuonc/nou347
[34] Grutters JP, Kessels AG, Pijls-Johannesma M, et al. Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: a meta-analysis[J]. Radiother Oncol, 2010, 95(1): 32-40.
[35] 王小虎, 田金徽, 张秋宁, 等.碳离子治疗前列腺癌的Meta分析[J].中华放射医学与防护杂志, 2016, 36(8): 588-593. doi: 10.3760/cma.j.issn.0254-5098.2016.08.007 Wang XH, Tian JH, Zhang QN, et al. A Meta-analysis of carbon ion radiotherapy for prostate cancer[J]. Zhonghua Fang She Yi Xue Yu Fang Hu Za Zhi, 2016, 36(8): 588-593. doi: 10.3760/cma.j.issn.0254-5098.2016.08.007
[36] Jolnerovski M, Salleron J, Beckendorf V, et al. Intensity-modulated radiation therapy from 70Gy to 80Gy in prostate cancer: six-year outcomes and predictors of late toxicity[J]. Radiat Oncol, 2017, 12(1): 99.
[37] Mizoe JE, Hasegawa A, Jingu K, et al. Results of carbon ion radiotherapy for head and neck cancer[J]. Radiother Oncol, 2012, 103(1): 32-37. https://pubmed.ncbi.nlm.nih.gov/22321201/
[38] Shinoto M, Yamada S, Yasuda S, et al. Phase 1 trial of preoperative, short-course carbon-ion radiotherapy for patients with resectable pancreatic cancer[J]. Cancer, 2013, 119(1): 45-51. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=9829a4c377ac2d276eb3fda5389b5bc4
[39] Thompson RF, Mayekar SU, Zhai H, et al. A dosimetric comparison of proton and photon therapy in unresectable cancers of the head of pancreas[J]. Med Phys, 2014, 41(8): 081711. https://pubmed.ncbi.nlm.nih.gov/25086521/
计量
- 文章访问数: 1587
- HTML全文浏览量: 353
- PDF下载量: 339
